Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | RARG | P13631 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638900 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1KIF11GAA | |
| SCHEMBL615379 | 0.86 | CA12 (0.62) | ALDH1A1LMNATSHRRARARARB | |
| SCHEMBL16838797 | 0.86 | KIF11 (0.51) | ALDH1A1KMT2AMEN1KIF11GAA | |
| SCHEMBL2470879 | 0.85 | NOTUM (0.62) | ALDH1A1KMT2AMEN1CYP2C9CYP2C19 | |
| SCHEMBL1190600 | 0.85 | CYP2C9 (0.44) | ALDH1A1KMT2AMEN1GAACYP2C9 | |
| SCHEMBL628125 | 0.85 | MAPK1 (0.54) | ALDH1A1KMT2AMEN1GAACYP2C9 | |
| SCHEMBL3548152 | 0.85 | GPBAR1 (0.46) | ALDH1A1KMT2AMEN1CYP2C9CYP2C19 | |
| SCHEMBL2773345 | 0.84 | RARA (0.61) | ALDH1A1KMT2AMEN1GAACYP2C9 | |
| SCHEMBL20342731 | 0.84 | S1PR1 (0.42) | KMT2AMEN1KIF11CYP2C9CYP2C19 | |
| SCHEMBL12336977 | 0.84 | THRA (0.45) | ALDH1A1KMT2AMEN1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741759-B1 | IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-C]PYRIMIDINE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF HYPERURICEMIA AND GOUT | EVOPOINT BIOSCIENCES CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3741759-B1 | IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-C]PYRIMIDINE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF HYPERURICEMIA AND GOUT | EVOPOINT BIOSCIENCES CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11453674-B2 | Heterocyclic compound, preparation method and use thereof in medicine | Evopoint Biosciences Co., Ltd. (CN) | 2022-09-27 | — | — | US | disclosed |
| EP-3741759-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741759-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-20200347070-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | SHANGHAI PUCHI BIOMEDICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200347070-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | SHANGHAI PUCHI BIOMEDICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| EP-3348557-B1 | IMIDAZO[1,2A]PYRIDINES FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2020-04-29 | — | — | EP | disclosed |
| EP-3348557-B1 | IMIDAZO[1,2A]PYRIDINES FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2020-04-29 | — | — | EP | disclosed |
| US-10399971-B2 | Compound for treating or preventing hyperuricemia or gout | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2019-09-03 | — | — | US | disclosed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | disclosed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | disclosed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | disclosed |
| EP-1701938-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | Genfit (FR) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005073184-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2005-08-11 | — | — | WO | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| US-5356893-A | Antidepressants, nervous system disorders | GLAXO GROUP LIMITED (GB) | 1994-10-18 | — | — | US | disclosed |
| EP-0533266-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | TYR, DHPS, DDT | ALDH1A1 7/4885KMT2A 2238/4885MEN1 1140/4885 |
| US-11453674-B2 | Heterocyclic compound, preparation method and use thereof in medicine | PAH, NLRP3, CYP11B2 | ALDH1A1 1562/4885KMT2A 2802/4885MEN1 272/4885 |
| US-20200347070-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | PAH, NLRP3, CYP11B2 | ALDH1A1 1562/4885KMT2A 2802/4885MEN1 272/4885 |
| US-10399971-B2 | Compound for treating or preventing hyperuricemia or gout | SLC10A1, SLC5A1, SLC10A6 | ALDH1A1 716/4885KMT2A 2744/4885MEN1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.